other_material
confidence high
sentiment positive
materiality 0.85
Rapport RAP-219 Phase 2a positive: 85.2% achieved ≥30% LE reduction, 24% seizure freedom
Rapport Therapeutics, Inc.
- 85.2% of patients achieved ≥30% reduction in long episodes (p<0.0001); median LE reduction 71%.
- 72% achieved ≥50% reduction in clinical seizures (p<0.0001); 24% seizure freedom; median reduction 77.8%.
- RAP-219 well tolerated: no SAEs; 78.5% of TEAEs mild; 10% discontinuation due to TEAEs.
- Company plans end-of-Phase 2 FDA meeting Q4 2025; Phase 3 pivotal trials expected Q3 2026.
- Additional programs: Phase 2 bipolar mania trial enrolling, topline H1 2027; diabetic neuropathic pain update later 2025.
item 7.01item 8.01item 9.01